A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients

SummaryWe evaluated the effects of diabetes on the risks of developing deep vein thrombosis (DVT) and pulmonary embolism (PE) in a nationwide, population-based cohort study in Taiwan. The patients with newly diagnosed type 2 diabetes mellitus (T2DM) were identified, and DM-free controls were randomly selected from the general population and frequency-matched according to age, sex, and index year by using the records of the Longitudinal Health Insurance Database between 2000 and 2011. Both cohorts were followed up until the end of 2011 to measure the incidence of DVT and PE. We analysed the risks of DVT and PE using Cox proportional-hazards regression models. The overall incidence of VTE was higher in the T2DM patients than in the controls (12.0 vs 7.51 per 10,000 person-years). The T2DM patients exhibited a 1.44-fold adjusted hazard ratio (aHR) of VTE development compared with the controls (95 % confidence interval [CI] = 1.27–1.63). The risks of DVT (aHR = 1.43, 95 % CI = 1.23–1.65) and PE (aHR = 1.52, 95 % CI = 1.22–1.90) were greater in the T2DM than those in the controls. The T2DM patients had a substantially higher risk of DVT (aHR = 5.10, 95 % CI = 3.12–8.32) and PE (aHR = 7.50, 95 % CI = 3.29–17.1) development than the controls did in adults aged 49 years and younger. In conclusion, the longitudinal nationwide cohort study indicated that T2DM patients carried greater risks of developing VTE than did the general population.

Download Full-text

Association between obstructive sleep apnea and deep vein thrombosis / pulmonary embolism: A population-based retrospective cohort study

Thrombosis Research ◽

10.1016/j.thromres.2014.06.009 ◽

2014 ◽

Vol 134 (2) ◽

pp. 340-345 ◽

Cited By ~ 24

Author(s):

Yi-Hao Peng ◽

Wei-Chih Liao ◽

Wei- Sheng Chung ◽

Chih-Hsin Muo ◽

Chia-Chen Chu ◽

...

Keyword(s):

Pulmonary Embolism ◽

Obstructive Sleep Apnea ◽

Cohort Study ◽

Deep Vein Thrombosis ◽

Sleep Apnea ◽

Retrospective Cohort ◽

Population Based ◽

Vein Thrombosis ◽

Obstructive Sleep ◽

Deep Vein

Download Full-text

Risk of pulmonary embolism and deep vein thrombosis in systemic lupus erythematosus: a population-based cohort study

Arthritis Research & Therapy ◽

10.1186/ar3987 ◽

2012 ◽

Vol 14 (S3) ◽

Cited By ~ 8

Author(s):

JA Aviña-Zubieta ◽

D Lacaille ◽

EC Sayre ◽

J Kopec ◽

HK Choi ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Pulmonary Embolism ◽

Cohort Study ◽

Deep Vein Thrombosis ◽

Lupus Erythematosus ◽

Population Based ◽

Systemic Lupus ◽

Vein Thrombosis ◽

Deep Vein

Download Full-text

The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-201669 ◽

2012 ◽

Vol 72 (7) ◽

pp. 1182-1187 ◽

Cited By ~ 60

Author(s):

Hyon K Choi ◽

Young-Hee Rho ◽

Yanyan Zhu ◽

Lucia Cea-Soriano ◽

Juan Antonio Aviña-Zubieta ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Pulmonary Embolism ◽

Cohort Study ◽

Deep Vein Thrombosis ◽

General Population ◽

Population Based ◽

Incidence Rates ◽

Vein Thrombosis ◽

Increased Risk ◽

Deep Vein

BackgroundRecent hospital-based studies have suggested a sixfold increased risk of pulmonary embolism (PE) in rheumatoid arthritis (RA) in the year following admission. We evaluated the risk of PE and deep vein thrombosis (DVT) and associated time trend among RA patients (84.5% without a history of hospitalisation during the past year) derived from the general population.MethodsWe conducted a cohort study using an electronic medical records database representative of the UK general population, collected from 1986 to 2010. Primary definitions of the RA cohort (exposure) and PE/DVT outcomes required physician diagnoses followed by corresponding treatments. We estimated relative risks (RRs) of PE and DVT compared with a matched non-RA comparison cohort, adjusting for age, sex, smoking, body mass index, comorbidities and hospitalisations.ResultsAmong 9589 individuals with RA (69% female, mean age of 58 years), 82 developed PE and 110 developed DVT (incidence rates, 1.5 and 2.1 per 1000 person-years). Compared with non-RA individuals (N=95 776), the age-, sex- and entry-time-matched RRs were 2.23 (95% CI 1.75 to 2.86) for PE and 2.20 (CI 1.78 to 2.71) for DVT. Adjusting for other covariates, the corresponding RRs were 2.16 (CI 1.68 to 2.79) and 2.16 (CI 1.74 to 2.69). The time-specific RRs for PE were 3.27, 1.88 and 2.35 for follow-up times of <1 year, 1–4.9 years, and ≥5 years, and corresponding RRs for DVT were 3.16, 1.82 and 2.32.ConclusionsThis population-based study indicates an increased risk of PE and DVT in RA, supporting increased monitoring of venous-thromboembolic complications and risk factors in RA, regardless of hospitalisation.

Download Full-text

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study

BMJ Open ◽

10.1136/bmjopen-2020-038102 ◽

2020 ◽

Vol 10 (11) ◽

pp. e038102

Author(s):

Alison Evans ◽

Miranda Davies ◽

Vicki Osborne ◽

Debabrata Roy ◽

Saad Shakir

Keyword(s):

Pulmonary Embolism ◽

Cohort Study ◽

Deep Vein Thrombosis ◽

Major Bleeding ◽

Secondary Care ◽

Observational Cohort Study ◽

Vein Thrombosis ◽

Prevention And Treatment ◽

Observational Cohort ◽

Deep Vein

ObjectivesTo evaluate the short-term (12 weeks) safety and utilisation of rivaroxaban prescribed to new-user adult patients for the treatment of deep vein thrombosis and pulmonary embolism and for the prevention of recurrent deep vein thrombosis and pulmonary embolism in a secondary care setting in England and Wales.DesignAn observational cohort study using the technique of Specialist Cohort Event Monitoring.SettingThe Rivaroxaban Observational Safety Evaluation study was conducted across 87 participating National Health Service secondary care trusts in England and Wales.Participants1532 patients treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism from September 2013 to January 2016.InterventionsNon-interventional postauthorisation safety study of rivaroxaban.Primary and secondary outcome measures(1) Risk of major bleeding in gastrointestinal, intracranial, and urogenital sites and (2) risk of all major and clinically relevant non-major bleeds.ResultsOf a total of 4846 patients enrolled in the study from September 2013 to January 2016, 1532 were treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism. The median age of the deep vein thrombosis/pulmonary embolism cohort was 63 years, and 54.6% were men. The risk of major bleeding within the gastrointestinal, urogenital and intracranial primary sites was 0.7% (n=11), 0.3% (n=5) and 0.1% (n=1), respectively. The risk of major bleeding in all sites was 1.5% (n=23) at a rate of 8.3 events per 100 patient-years.ConclusionsIn terms of the primary outcome risk of major bleeding in gastrointestinal, intracranial and urogenital sites, the risk estimates in the population using rivaroxaban for deep vein thrombosis/pulmonary embolism were low (<1%) and consistent with the risk estimated from clinical trial data and in routine clinical practice.Trial registration numbersClinicalTrials.gov Registry (NCT01871194); ENCePP Registry (EUPAS3979).

Download Full-text